ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0649

Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity

Marc Scherlinger1, Wenliang Pan2, Ryo Hisada1, Milena Vukelic3, Masataka Umeda1, Afroditi Boulougoura2, Maria Tsokos1 and George Tsokos2, 1BIDMC Harvard University, Boston, MA, 2Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Albert Einstein College of Medicine, New York, NY

Meeting: ACR Convergence 2022

Keywords: immunology, metabolomics, Systemic lupus erythematosus (SLE), T Cell, Treg cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a defective T regulatory (Treg) cell compartment which participate in immune dysregulation. Although the underlying mechanism are unknown, dysregulated T cell metabolism has been widely reported in SLE, and its normalization leads to disease improvement (1). Calcium/calmodulin dependent protein kinase (CaMK4) activity is increased in SLE and has been shown to affect T cell metabolism (2). Our objective was to investigate the mechanisms underlying Treg cell metabolic dysregulation in SLE, with a focus on CaMK4.

Methods: We harvested CD62L+CD4+ T cells from wild-type (WT) or Camk4-/- mice and differentiated them in vitro into inducible Treg (iTreg) cells. We evaluated iTreg metabolism using Seahorse XF analyzer and mass spectrometry (metabolomics). Phosphofructokinase activity was assessed by a colorimetric assay (Abcam). In vitro gene knockdown was conducted by transfecting a guide RNA (gRNA) in CRISPR/Cas9-expressing T cells. Treg cell function was evaluated by in vitro immunosuppressive assay and in vivo by the adoptive transfer of T conventional T and iTreg cells (8:1 ratio) in Rag1-/- mice to induce inflammatory colitis. The relevance of CaMK4 in SLE was evaluated in vivo using a T-cell specific knockdown of CaMK4 in the B6.lpr mouse model, and in humans by culturing SLE patient T cells with KN-93, a CaMK4 specific inhibitor.

Results: iTreg cells from Camk4-/- mice had decreased glycolysis and increased mitochondrial metabolism compared to WT mice. Metabolomics studies suggested decreased activity of the rate-limiting glycolysis enzyme phosphofructokinase platelet-type (PFKP). While PFKP mRNA and protein levels were similar between WT and Camk4-/- iTreg, PFKP activity was significantly decreased in Camk4-/- iTreg, suggesting a post-transcriptional control of PFKP activity by CaMK4. Mechanistically, immunoprecipitation experiments confirmed that CaMK4 interacted with PFKP, and phosphoproteomic study suggested that CaMK4 phosphorylated serine residue 539 of PFKP, a site known to control PFKP activity. To confirm the importance of PFKP in Treg biology, we showed that PFKP knockdown significantly improved iTreg function in vitro (p < 0.01) and in vivo using an adoptive colitis model (Fig. 1A-B). In vivo, iTreg lacking PFKP were less likely to lose FoxP3 expression (Fig. 1C) and to produce IL-17A, demonstrating higher Treg stability in an inflammatory environment. On a translational basis, lupus-prone B6.lpr mice with a T-cell specific CaMK4 knockdown displayed improved disease pathology. Human SLE CD4+ T cells had higher PFKP activity compared to healthy donors, and PFKP activity correlated with the SLE disease activity index (SLEDAI, r = 0.579, p < 0.005; Fig. 2A-B). Finally, culture of SLE CD4+ T cells with KN-93 led to a significant decrease in PFKP activity (p < 0.001, Fig. 2C), and an improvement of Treg cell immunosuppressive activity (Fig. 2D-E).

Conclusion: By fine-tuning their immunometabolism, PFKP controls the immunosuppressive function and stability of Treg cell in SLE, and represents a promising therapeutic target.

References: 
1. Yin Y, et al. Sci Transl Med. 7(274):274ra18.
2. Kono M, et al. JCI Insight 4(12):e127395.

Supporting image 1

Figure 1: PFKP modulation improves the iTreg cell in vivo function and stability in the adoptive transfer colitis model.
(A) Design of the in vivo experiment. Cas9-GFP expressing CD62L+ CD4+ T cells were transfected with control of Pfkp-target sgRNA and differentiated into iTreg cells. CD45RBhi CD4+ T (Tconv) cells were sorted using FACS from CD4+ T cells presorted from the splenocytes of C57Bl/6 mice. T-deficient RAG1-/- mice were transferred with 4×106 Tconv and 5×105 iTreg. Data are from 3 independent experiments of 2_3 mice per condition. (B) Weight of mice transferred with Tconv cells only (purple, n = 4), Tconv and control iTreg cells (red, n = 8) or Tconv and Pfkp-target iTreg cells (blue, n = 8). After sacrifice, the percentage of CD25+FoxP3+ Treg cells was evaluated among initially transferred iTreg identified as GFP+ CD4+ T cells, in the spleen and mesenteric lymph nodes (mLN; n = 8). Points and bars represent an individual value and s.e.m., respectively. **, p < 0.01; ***, p < 0.001.

Supporting image 2

Figure 2: CaMK4 regulates PFKP activity in SLE CD4+ T cells and impairs human Treg cell immunosuppressive functions.
(A) PFK activity was measured from the lysate of CD4+ T cells cultured during 24 hours with CD3/CD28 activation. Samples from HD (n = 11) and SLE patients (n = 22). (B) Spearman correlation of the CD4+ T cells PFK activity and the SLE disease activity index (SLEDAI; n = 22).The delimited grey area indicates the 95% confidence interval of the linear regression. (C) PFK activity was measured from the lysate of CD4+ T cells cultured during 24 hours with CD3/CD28 activation with or without KN93 (10μM; n = 22). (D) Representative results of Tconv cells proliferation. (F) The percentage of immunosuppression was calculated by comparing Treg/Tconv cell proliferation to the Tconv cell proliferation from the corresponding condition (n = 4 biological replicates). Points and bars represent an individual value and s.e.m., respectively. **, p < 0.01.


Disclosures: M. Scherlinger, Sandoz, Amgen, Nordic Pharma; W. Pan, None; R. Hisada, None; M. Vukelic, None; M. Umeda, None; A. Boulougoura, None; M. Tsokos, None; G. Tsokos, None.

To cite this abstract in AMA style:

Scherlinger M, Pan W, Hisada R, Vukelic M, Umeda M, Boulougoura A, Tsokos M, Tsokos G. Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/phosphofructokinase-p-fine-tunes-t-regulatory-cell-metabolism-function-and-stability-in-systemic-autoimmunity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phosphofructokinase-p-fine-tunes-t-regulatory-cell-metabolism-function-and-stability-in-systemic-autoimmunity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology